Code Pharma has reported positive results from an eight-week study of Gammora®, showing promise for a potential HIV cure at the cellular level. Preliminary data were shared at the 2024 HIV Drug Therapy Conference in Glasgow, Scotland.
Gammora is a peptide based on HIV-1 integrase that targets HIV-infected cells by inserting viral genetic material into their DNA. In an open-label, randomized trial, Gammora used alongside protease inhibitor (PI)-based antiretroviral therapy (ART) effectively reduced the HIV reservoir—the group of HIV-infected cells—without harming surrounding healthy cells, a limitation often seen with traditional ART drugs.
“These incredibly positive outcomes offer new hope at a time when 40 million individuals worldwide are impacted by HIV and the current standard of care with ART drugs does not offer a cure at the cellular level,” said Eynat Finkelshtein, PhD., Chief Scientific Officer of Code Pharma.